Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

Novo Nordisk has achieved great success in weight management thanks to its diabetes and obesity care medications, Ozempic and Wegovy. Viking Therapeutics is looking to make inroads in the obesity ...

Just days after Eli Lilly announced plans to cut the price of its insulin products in the US, Novo Nordisk has followed suit with reductions of up to 75% from the start of next year. The discount ...

All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the ...

Weight loss treatment provider Novo Nordisk has seen a 12% stock price ... position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.

Novo Nordisk’s weight loss drug Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, results the company sees as ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up. Less than a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...